ERBB2 and breast cancer: HER2 + inhibitors such as trastuzumab and pertuzumab are not only widely used in breast cancer, but also other HER-positive diseases such as colorectal cancer, metastatic gastric cancer, biliary tract cancer, and leptomeningeal disease due to the susceptibility gene and PI3K-signaling pathway [52–54].